Heather S. Han, MD, discusses the importance of pathologic complete response in breast cancer.
Heather S. Han, MD, medical oncologist and research director of Breast Oncology, Moffitt Cancer Center, discusses the importance of pathologic complete response (pCR) in breast cancer.
Patients with breast cancer who achieve a pCR following neoadjuvant therapy often have a better outcome compared with patients who do not, Han says. Moreover, pCR has been established as an important prognostic marker in breast cancer.
Today, pCR continues to be used as a surrogate marker for patients with breast cancer following neoadjuvant therapy, explains Han.
Based on available data, the field can better determine the most optimal adjuvant treatment option for patients, Han concludes.